ArticleFrontiers in pharmacology2021

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.

Yueying Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.